United States Radioligand Therapy industry Revolutionizing Prostate Cancer Treatment | Technology Advancements and Innovation 2025

"The global Radioligand Therapy Market size reached US$ 2.41 billion in 2024 and is expected to reach US$ 15.80 billion by 2033, growing at a CAGR of 21.9% during the forecast period 2025-2033".As per DataM intelligence research report.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/radioligand-therapy-market?oppratik

United States: Recent Industry Developments:

✅ In March 2025, Novartis received FDA approval for its radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer patients in the US.

✅ In June 2025, Mariana Oncology, a Novartis company, announced a $50 million expansion of its radioligand therapy R&D facilities in Watertown, Massachusetts, doubling its footprint to accelerate the development of next-generation RLTs for cancer treatment.

Japan: Recent Industry Developments:

✅ In August 2025, a Japanese health ministry panel reviewed Novartis' radioligand therapy lutetium vipivotide tetraxetan for approval, signaling a potential regulatory advancement for RLTs in Japan.

✅ In September 2025, reports indicated Japan's growing adoption of radioligand therapy driven by oncology applications like prostate cancer and neuroendocrine tumors, supported by increasing infrastructure investments, government initiatives, and expanded insurance coverage to enhance patient access.

Latest Mergers & Acquisitions (M&A):

In January 2025, Lantheus completed the acquisition of Evergreen Theragnostics for $1 billion, expanding its radioligand therapy manufacturing capabilities and product portfolio.

In May 2024, Novartis agreed to acquire Mariana Oncology, a preclinical-stage biotech focused on novel radioligand therapies, enhancing its RLT pipeline.

In June 2025, Bristol Myers Squibb acquired RayzeBio for $4.1 billion to strengthen its oncology radioligand therapy portfolio.

In June 2025, AstraZeneca acquired Fusion Pharmaceuticals for $2.4 billion, aiming to advance its radioligand therapy offerings in cancer treatment.

Recent Investments:

-In July 2025, ARTBIO raised $132 million in a Series B funding round led by Sofinnova Investments and B Capital, to advance its alpha radioligand therapy pipeline and manufacturing infrastructure.

-In July 2025, Actithera secured $75.5 million in an oversubscribed Series A financing to develop its fibroblast activation protein (FAP) targeting radioligand therapy candidate and expand its discovery platform.

Key Players:
-Novartis AG and Bayer AG.

Research Process:

Both primary and secondary data sources have been used in the global Radioligand Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market?oppratik

Market Segments:

By Type- Lutetium Lu-177, Radium Ra 223 Dichloride, Others

By Target- Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR)),

By Application- Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumours GEP-NETs Others

Latest News-

-Novartis received FDA approval for Pluvicto® for earlier use in prostate cancer, marking a significant milestone in RLT adoption in the US.

-Major pharmaceutical players like Bristol Myers Squibb and AstraZeneca are actively acquiring radioligand therapy companies to expand their oncology portfolios.

-Several startups, such as ARTBIO and Actithera, are rapidly advancing innovative radioligand therapies with substantial funding support.

-Japan is preparing regulatory reviews for new radioligand drugs, aiming to accelerate approvals and integration into clinical practice soon.

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/radioligand-therapy-market?oppratik

Recent FDA Approval:-

✅ On October 1, 2025, the FDA approved a new combination radioligand therapy regimen aimed at improving outcomes in metastatic neuroendocrine tumors, enhancing treatment effectiveness.

✅ On September 15, 2025, the FDA granted breakthrough therapy designation to a novel alpha-emitting radioligand under development by ARTBIO for treatment-resistant prostate cancer.

✅ On August 9, 2025, the FDA updated labeling for Novartis' Pluvicto® expanding its indicated use to earlier stages of metastatic castration-resistant prostate cancer.

✅ On July 9, 2025, the FDA approved a new diagnostic radioligand imaging agent to detect aggressive prostate cancers with improved sensitivity.

The main drivers of the Radioligand Therapy market -

Increasing cases of hard-to-treat cancers like prostate and neuroendocrine tumors.

Advances in radioligand technology improve targeting cancer cells with fewer side effects.

More drug approvals and faster regulatory support help new treatments reach patients quickly.

Big investments and partnerships boost research and development activities.

FAQ's

Q1: What is the current size of the Radioligand Therapy Market?

A: The Radioligand Therapy Market stood at US$ 2.41 billion in 2024 and is set to experience remarkable growth, reaching US$ 15.80 billion by 2033

Q2: How fast is the Radioligand Therapy Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 21.9% from 2025 to 2033

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us-

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.